
Foxy-5
CAS No. 881188-51-8
Foxy-5( formyl-Met-Asp-Gly-Cys-Glu-Leu | Foxy5 )
Catalog No. M16389 CAS No. 881188-51-8
Foxy-5 is a novel Wnt-5A mimicking hexapeptide that inhibits breast cancer metastasis in vivo by targeting cell motility.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameFoxy-5
-
NoteResearch use only, not for human use.
-
Brief DescriptionFoxy-5 is a novel Wnt-5A mimicking hexapeptide that inhibits breast cancer metastasis in vivo by targeting cell motility.
-
DescriptionFoxy-5 is a novel Wnt-5A mimicking hexapeptide that inhibits breast cancer metastasis in vivo by targeting cell motility; also significantly inhibits the initial metastatic dissemination of prostate cancer cells to regional and distal lymph nodes, specifically targets invasion without affecting apoptosis or viability of WNT5A-low prostate cancer cells. Breast Cancer Phase 1 Clinical.
-
In Vitro——
-
In VivoFoxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.Foxy-5 reduces the number of colonic cancer stem cells in a xenograft mouse model of human colonic cancer.
-
Synonymsformyl-Met-Asp-Gly-Cys-Glu-Leu | Foxy5
-
PathwayWnt/Notch/Hedgehog
-
TargetWnt/beta/catenin
-
RecptorWnt/beta/catenin
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number881188-51-8
-
Formula Weight694.77
-
Molecular FormulaC26H42N6O12S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC(C)C[C@@H](C(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CS)NC(CNC([C@H](CC(O)=O)NC([C@H](CCSC)NC=O)=O)=O)=O)=O)=O
-
Chemical Name(2S,5S,8R,14S)-5-(2-carboxyethyl)-14-((S)-2-formamido-4-(methylthio)butanamido)-2-isobutyl-8-(mercaptomethyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazahexadecanedioic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. S?fholm A, et al. Clin Cancer Res. 2008 Oct 15;14(20):6556-63.
2. Ford CE, et al. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3919-24.
3. Canesin G, et al. PLoS One. 2017 Sep 8;12(9):e0184418.
molnova catalog



related products
-
KY-05009
KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells.
-
ICG-001
ICG-001 is an antagonist of Wnt/β-catenin/TCF-mediated transcription and specifically binds to element-binding protein (CBP) with IC50 of 3 μM.
-
Cardiogenol C hydroc...
Cardiogenol C hydrochloride can induces the differentiation of ESCs into cardiomyocytes (EC50= 100 nM).